Study identifier:D1710C00025
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase I, Single Centre, Open-label Study to Assess the Pharmacokinetics of Both AZD5672 (Steady-state) and Atorvastatin (Single Dose) When Co administered in Healthy Volunteers
Healthy Volunteers, pharmacokinetics
Phase 1
Yes
AZD5672, atorvastatin
All
12
Interventional
18 Years - 55 Years
Allocation: Non-randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
The purpose of the study is to assess the pharmacokinetics of both AZD5672 (steady-state) and atorvastatin (single dose) when co administered in healthy volunteers
Location
Location
London, United Kingdom
Arms | Assigned Interventions |
---|---|
Experimental: 1 AZD5672 + atorvastatin | Drug: AZD5672 100 mg once daily, 10 days Drug: atorvastatin one single dose of 40 mg on day 10 Other Name: Lipitor® |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.